Search - tctmd.com

Displaying 81 - 100 of 155

Sort: Relevancy | Date

News Daily News

Real-world Analysis Suggests Apixaban Is Safest of the NOACs, Even for Patients With A-fib

L.A. McKeown

July 06, 2018

News Daily News

New Review Probes Possibility of CVD Prevention Without Aspirin

Michael O'Riordan

July 04, 2018

News Daily News

‘Doomed’ by Genetics? Lifestyle Still Matters in Preventing CVD and Diabetes

Yael L. Maxwell

June 29, 2018

News Daily News

NOACs Carry Lower MI Risk vs Warfarin in Real-world Study

Todd Neale

June 25, 2018

Will Percutaneous Mitral Repair Catch Up or Surpass Surgery? Experts Make Their Predictions

Shelley Wood

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

A Rare Case of Platypnea-Orthodeoxia Syndrome Developing After Atrial Fibrillation Ablation Necessitating Percutaneous Closure of the Septal Puncture Site

Presenter: Horst Sievert, Robert J. Sommer, Nadim Geloo, MD

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Indications and Uncertainties for Atrial Fibrillation Treatment: Risk Scores, Single AF Episode, Post-CABG AF, Valvular vs. Nonvalvular, and More

Presenter: William A. Gray, Gregg W. Stone, Vivek Y. Reddy

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Atrial Fibrillation + PCI: The Myths and Realities of Triple Therapy

Presenter: Anthony N. DeMaria, Vivek Y. Reddy, Ashish Pershad

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Pharmacologic Agents to Prevent Stroke in Nonvalvular Atrial Fibrillation and PFO: Evidence and Real-world Practices

Presenter: Anthony N. DeMaria, Vivek Y. Reddy, Gregg W. Stone

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

An Introduction to the WATCH-TAVR Trial Combining TAVR and LAAC

Presenter: Amar Krishnaswamy

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

European Perspectives and Updates From a Randomized Trial Combining TAVR and LAAC

Presenter: Fabian Nietlispach

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Pharmacotherapy Considerations Trials and Practical Clinical Recommendations

Presenter: George D. Dangas

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

A Growing Conundrum: Coronary Access After TAVR Technical Tips and Tricks

Presenter: James B. Hermiller Jr

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Management of Coronary Disease in AS Patients: Important Treatment Considerations (When to Consider CABG, Timing of PCI and TAVR, and Completeness of Revascularization)

Presenter: Torsten P. Vahl

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

The Role of MitraClip After TAVR: A Case-Based Tutorial (Who, When, and How)

Presenter: Hüseyin Ince

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Clinical Decision-Mmaking in AS and MR Patients: Choosing the Best Patients for Multivalve Interventions

Presenter: Anita Asgar

June 21, 2018

News Daily News

Do Not Screen Asymptomatic Adults For CVD With ECGs, Says USPSTF

Michael O'Riordan

June 12, 2018

News Daily News

Silent A-fib That Progresses Signals a Higher Heart Failure Risk

Todd Neale

June 06, 2018

News Daily News

Biomarkers, New Data, and Revised Methods Boost Accuracy of the ACC/AHA Risk Equations

Todd Neale

June 04, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2018

Caitlin E. Cox

June 01, 2018

Advertisement

Real-world Analysis Suggests Apixaban Is Safest of the NOACs, Even for Patients With A-fib

New Review Probes Possibility of CVD Prevention Without Aspirin

‘Doomed’ by Genetics? Lifestyle Still Matters in Preventing CVD and Diabetes

NOACs Carry Lower MI Risk vs Warfarin in Real-world Study

Will Percutaneous Mitral Repair Catch Up or Surpass Surgery? Experts Make Their Predictions

A Rare Case of Platypnea-Orthodeoxia Syndrome Developing After Atrial Fibrillation Ablation Necessitating Percutaneous Closure of the Septal Puncture Site

Indications and Uncertainties for Atrial Fibrillation Treatment: Risk Scores, Single AF Episode, Post-CABG AF, Valvular vs. Nonvalvular, and More

Atrial Fibrillation + PCI: The Myths and Realities of Triple Therapy

Pharmacologic Agents to Prevent Stroke in Nonvalvular Atrial Fibrillation and PFO: Evidence and Real-world Practices

An Introduction to the WATCH-TAVR Trial Combining TAVR and LAAC

European Perspectives and Updates From a Randomized Trial Combining TAVR and LAAC

Pharmacotherapy Considerations Trials and Practical Clinical Recommendations

A Growing Conundrum: Coronary Access After TAVR Technical Tips and Tricks

Management of Coronary Disease in AS Patients: Important Treatment Considerations (When to Consider CABG, Timing of PCI and TAVR, and Completeness of Revascularization)

The Role of MitraClip After TAVR: A Case-Based Tutorial (Who, When, and How)

Clinical Decision-Mmaking in AS and MR Patients: Choosing the Best Patients for Multivalve Interventions

Do Not Screen Asymptomatic Adults For CVD With ECGs, Says USPSTF

Silent A-fib That Progresses Signals a Higher Heart Failure Risk

Biomarkers, New Data, and Revised Methods Boost Accuracy of the ACC/AHA Risk Equations

TCTMD’s Top 10 Most Popular Stories for May 2018

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content